1. Home
  2. GLOB vs ODTX Comparison

GLOB vs ODTX Comparison

Compare GLOB & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globant S.A.

GLOB

Globant S.A.

N/A

Current Price

$41.60

Market Cap

1.3B

Sector

Technology

ML Signal

N/A

Logo Odyssey Therapeutics Inc. Common Stock

ODTX

Odyssey Therapeutics Inc. Common Stock

N/A

Current Price

$16.85

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GLOB
ODTX
Founded
2003
2021
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
GLOB
ODTX
Price
$41.60
$16.85
Analyst Decision
Buy
Strong Buy
Analyst Count
23
8
Target Price
★ $52.10
$34.67
AVG Volume (30 Days)
★ 1.0M
291.0K
Earning Date
11-19-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.28
N/A
P/E Ratio
$22.55
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.56
$15.10
52 Week High
$72.10
$29.05

Technical Indicators

Market Signals
Indicator
GLOB
ODTX
Relative Strength Index (RSI) 40.75 36.09
Support Level $34.29 $15.73
Resistance Level $44.64 $19.60
Average True Range (ATR) 2.16 1.69
MACD -1.09 -0.19
Stochastic Oscillator 12.42 6.10

Price Performance

Historical Comparison
GLOB
ODTX

About GLOB Globant S.A.

Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.

About ODTX Odyssey Therapeutics Inc. Common Stock

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Share on Social Networks: